A number of other research analysts have also weighed in on the stock. ValuEngine raised shares of Ritter Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, October 2nd. Zacks Investment Research lowered shares of Ritter Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, July 18th.
Shares of Ritter Pharmaceuticals stock opened at $1.72 on Monday. Ritter Pharmaceuticals has a twelve month low of $1.40 and a twelve month high of $4.15.
In other Ritter Pharmaceuticals news, Director Matthew W. Foehr bought 19,751 shares of the firm’s stock in a transaction on Friday, August 17th. The shares were acquired at an average cost of $2.04 per share, with a total value of $40,292.04. Following the purchase, the director now directly owns 54,751 shares of the company’s stock, valued at approximately $111,692.04. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 21.60% of the company’s stock.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
Recommended Story: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.